{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'discontinuation of IP as defined in Appendix 6 (Section 10.6, Table 6) with the exception of', 'events for which subjects cannot be monitored. Follow-up liver laboratory values (Table 4),', 'Appendix 2 [Section 10.2]) and additional information to characterize the etiology of the event', 'are mandatory and specified in Appendix 6 (Section 10.6, Table 6).', '10.3.4.', 'Recording and Follow Up of Adverse Events and Serious Adverse Events', 'AE and SAE Recording', 'When an AE/SAE occurs, it is the responsibility of the investigator to review all', 'documentation (eg, hospital progress notes, laboratory reports, and diagnostics reports) related', 'to the event.', 'The investigator will then record all relevant AE/SAE/AE of Interest information in the eCRF.', \"It is not acceptable for the investigator to send photocopies of the subject's medical records to\", 'the Sponsor in lieu of completion of the AE/SAE eCRF page.', 'There may be instances when copies of medical records for certain cases are requested by the', 'Sponsor. In this case, all subject identifiers, with the exception of the subject number, will be', 'redacted on the copies of the medical records before submission to the Sponsor.', 'The investigator will attempt to establish a diagnosis of the event based on signs, symptoms,', 'and/or other clinical information. Whenever possible, the diagnosis (not the individual', 'signs/symptoms) will be documented as the AE/SAE.', 'Assessment of Intensity', 'The investigator will assess intensity for each AE and SAE reported during the study and assign it', 'to 1 of the following categories:', 'Mild: An event that is easily tolerated by the subject, causing minimal discomfort and not', 'interfering with everyday activities.', 'Moderate: An event that causes sufficient discomfort and interferes with normal everyday', 'activities.', 'Severe: An event that prevents normal everyday activities. An AE that is assessed as severe', 'should not be confused with a SAE. Severe is a category utilized for rating the intensity of an', 'event; and both AEs and SAEs can be assessed as severe.', \"An event is defined as 'serious' when it meets at least 1 of the predefined outcomes as\", 'described in the definition of an SAE, NOT when it is rated as severe.', '57', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Assessment of Causality', 'The investigator is obligated to assess the relationship between IP and each occurrence of each', 'AE/SAE.', '- Related - The AE is known to occur with the IP, there is a reasonable possibility that the', 'IP caused the AE, or there is a temporal relationship between the IP and event. Reasonable', 'possibility means that there is evidence to suggest a causal relationship between the IP and', 'the AE.', '-', 'Not Related - There is not a reasonable possibility that the administration of the IP caused', 'the event, there is no temporal relationship between the IP and event onset, or an alternate', 'etiology has been established.', 'The investigator will use clinical judgment to determine the relationship.', 'Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors,', 'as well as the temporal relationship of the event to IP administration will be considered and', 'investigated.', \"The investigator will also consult the Investigator's Brochure (IB) and/or Product Information,\", 'for marketed products, in his/her assessment.', 'For each AE/SAE, the investigator must document in the medical notes that he/she has', 'reviewed the AE/SAE and has provided an assessment of causality.', 'There may be situations in which an SAE has occurred, and the investigator has minimal', 'information to include in the initial report to the Sponsor. However, it is very important that', 'the investigator always assess causality for every event before the initial transmission of', 'the SAE data to the Sponsor.', 'The investigator may change his/her opinion of causality in light of follow-up information', 'and send a SAE follow-up report with the updated causality assessment.', 'The causality assessment is one of the criteria used when determining regulatory reporting', 'requirements.', 'Follow-up of AEs and SAEs', 'The investigator is obligated to perform or arrange for the conduct of supplemental', 'measurements and/or evaluations as medically indicated or as requested by the Sponsor to', 'elucidate the nature and/or causality of the AE or SAE as fully as possible. This may include', 'additional laboratory tests or investigations, histopathological examinations, or consultation', 'with other health care professionals.', 'If a subject dies during participation in the study or during a recognized follow-up period, the', 'investigator will provide the Sponsor with a copy of any post-mortem findings including', 'histopathology if available.', 'New or updated information will be recorded in the originally completed eCRF.', 'The investigator will submit any updated SAE data to the Sponsor within 24 hours of receipt of', 'the information.', '58', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}